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Abstract
Background: To investigate the associations between atorvastatin-induced liver injury (AILI) and polymorphisms in
eight genes possibly involved in the hepatic metabolism (CYP2C9, CYP2C19, CYP3A4, CYP3A5 and UGT1A1) and
membrane transport (ABCB1, ABCG2 and SLCO1B1) of atorvastatin, we genotyped 30 AILI and 414 non-AILI patients
recruited at BioBank Japan for 15 single nucleotide polymorphisms (SNPs).
Results: An SNP in ABCB1 (rs2032582: 2677G > T/A) was significantly associated with AILI (P = 0.00068, odds ratio
(OR) = 2.59 with 95 % confidence interval (CI) of 1.49-4.50, G allele versus T and A alleles), indicating that the G allele
might be a risk factor for AILI. The cytotoxicity test demonstrated that IC50 value of atorvastatin to inhibit the
growth and/or viability of Flp-In-293/ABCB1 (2677G) cells was 5.44 ± 0.10 mM, which was significantly lower than
those in Flp-In-293/ABCB1 (2677 T) (6.02 ± 0.07 mM) and Flp-In-293/ABCB1 (2677A) cells (5.95 ± 0.08 mM).
Conclusions: These results indicate that ABCB1 rs2032582 may predict the risk of AILI in Japanese population.
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Background
Atorvastatin (atorvastatin calcium; Lipitor®) is widely
used in the treatment of dyslipidemia of low- and high-
density lipoproteins in patients with or without heart
disease [1]. However, atorvastatin-induced liver injury
(AILI) can be caused after atorvastatin treatment [1, 2].
In Japanese post-marketing surveillance of atorvastatin,
1.42 % of patients who received atorvastatin treatment
suffered from liver injury. In general, drug-induced liver
injury (DILI) can be divided into 3 types (hepatocellular
injury, cholestatic liver injury and mixed liver injury)
based on potential liver toxicity symptoms (e.g., an-
orexia, nausea, vomiting or jaundice), the presence or
absence of risk factors (e.g., viral infection and alcohol
consumption) and serum levels of alanine aminotrans-
ferase (ALT) and alkaline phosphatase (ALP) as well as
the ALT/ALP ratio [3]. AILI falls within the hepatocellu-
lar injury category because ALT level of two patients
treated with atorvastatin reportedly raised three-fold
higher than that of the upper limit of normal but ALP
and bilirubin levels did not change [4].
Atorvastatin is orally administered in the active acid
form and undergoes marked first-pass metabolism by up-
take into hepatocytes via passive diffusion and SLCO1B1
(encoding OATP1B1 [5–7]. Atorvastatin is metabolized
mainly by CYP3A4, with minor contributions from
CYP2C9, CYP2C19, CYP3A5, and UGT1A1 [8–12]. Subse-
quently, atorvastatin and the metabolites are predomin-
antly eliminated by ABCB1 (encoding P-glycoprotein or
MDR1)- and ABCG2 (encoding BCRP)-mediated trans-
port from liver into bile [7, 13–15]. Single nucleotide
polymorphisms (SNPs) identified in ABCB1 rs1128503
(1236C > T), rs2032582 (2677G > T/A), and rs1045642
(3435C > T) markedly affected area under the plasma con-
centration versus time curve (AUC) of atorvastatin and
the lipid-lowering effects of atorvastatin therapy [16–18].
Therefore, we hypothesized that the genetic variability of
eight candidate genes associated with the hepatic metabol-
ism and membrane transport of atorvastatin may affect
the risk of AILI because higher concentrations of atorva-
statin can cause hepatocellular injury, even at appropriate
atorvastatin dosages. However, to our knowledge, there
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are no reports on an association of the functional SNPs of
the candidate genes with AILI.
In this study, we investigated whether 15 functional
SNPs in eight candidate genes that are possibly involved
in the pharmacokinetics of atorvastatin were associated
with AILI in Japanese population. We found that ABCB1
rs2032582 was significantly associated with AILI. In
addition, the cytotoxicity of atorvastatin was investigated
using the Flp-In-293 cells stably expressing ABCB1 pro-
teins encoded by ABCB1 rs2032582 [19]. We clarified
that the ABCB1 rs2032582 G allele was a significant
AILI risk factor in vivo and in vitro.
Methods
Subjects
The BioBank Japan project (https://biobankjp.org/)
started in 2003 for the collection of genomic DNA,
serum and clinical information from about 300,000 Japanese
patients diagnosed with either of 47 diseases by a collab-
orative network of 66 hospitals in Japan. We diagnosed
AILI based on symptoms, such as nausea, vomiting, loss
of appetite, and jaundice, and results of a physical examin-
ation and blood tests after atorvastatin administration.
From the registered samples in the BioBank Japan, we se-
lected individuals that were clinically diagnosed as having
AILI (AILI group, N = 30) and individuals that showed no
liver injury during atorvastatin therapy (non-AILI group,
N = 414).
Selection of SNPs and genotyping
A total of 15 functional SNPs in eight candidate genes
(ABCB1, ABCG2, CYP2C9, CYP2C19, CYP3A4, CYP3A5,
SLCO1B1 and UGT1A1) reportedly-altering pharmaco-
kinetics of atorvastatin were genotyped by a multiplex
polymerase chain reaction (PCR)–based invader assay as
described previously [20] and direct sequencing using
ABI 3730xl DNA analyzer (Applied Biosystems, Foster
City, CA) for rs8175347 and rs2032582, according to the
manufacturer’s protocol of the Big Dye Terminator
v3.1 cycle sequencing kit (Applied Biosystems). HLA-A,
-B and -C genotyping was carried out using a WAKFlow
HLA Typing kit (Wakunaga, Osaka, Japan), which is
based on PCR-sequence-specific oligonucleotide probes
coupled with multiple analyte profiling (xMAP) technol-
ogy (Luminex System; Luminex Corporation, Austin, TX).
The data analysis was performed using the WAKFlow
Typing software (Wakunaga).
Cell culture
HepaRG cells (KAC, Kyoto, Japan) were maintained in
HepaRG Thawing and Seeding Medium 670 (KAC) and
HepaRG Maintenance and Metabolism medium 620
(KAC) at 37 °C under 5 % CO2 and 95 % air according
to the manufacturer’s instructions. Flp-In-293 cells (Life
Technologies, Foster City, CA) were maintained in
Dulbecco’s modified Eagle’s medium (Life Technologies)
supplemented with 10 % heat-inactivated fetal bovine
serum (Life Technologies) and Antibiotic-Antimycotic
(100×) liquid (Life Technologies) at 37 °C under 5 %
CO2 and 95 % air, where 100 μg/ml Zeocin (Life
Technologies) and 100 μg/ml hygromycin B (Life Tech-
nologies) were also supplemented for the maintenance
for parental and ABCB1-expressed Flp-In-293 cells,
respectively.
Generation of ABCB1 2677G/T/A variant forms
The pcDNA5/FRT/ABCB1 (2677G) vector was generated
by inserting ABCB1 (2677G) in pFastBac1/ABCB1
(2677G) into the pcDNA5/FRT vector (Life Technologies)
between the restriction enzyme sites of BamH I and Xho I.
ABCB1 2677 T/A variant forms were generated by using
the QuikChange Site-directed Mutagenesis Kit (Agilent
Technologies, Santa Clara, CA) according to the manufac-
turer’s protocol, where pcDNA5/FRT/ABCB1 (2677G)
vector was used as the template [21]. The PCR reaction
consisted of 94 °C for 2 min and then followed by 12 cycles
of reactions at 94 °C for 30 sec, 55 °C for 30 sec and at
68 °C for 18 min, where Pfu Turbo DNA polymerase
(Agilent Technologies) and the following PCR primers
were used: 5’-GAAAGAACTAGAAGGTTCTGGGAA
GATCGCTAC-3’ and 5’-GTAGCGATCTTCCCAGAAC
CTTCTAGTTCTTTC-3’ for ABCB1 2677 T, and 5’-
GAAAGAACTAGAAGGTACTGGGAAGATCGCTAC-
3’ and 5’-GTAGCGATCTTCCCAGTACCTTCTAGTTC
TTTC-3’ for ABCB1 2677A. After the PCR, the reaction
mixture was incubated with DpnI endonuclease at 37 °C
for 1 h to digest the original template pcDNA5/FRT/
ABCB1 (2677G) vector. The resulting sequence was exam-
ined to confirm the generation of the pcDNA5/FRT/
ABCB1 (2677G/T/A) vectors.
Establishment of ABCB1 2677G/T/A variant forms-
expressing cells
Flp-In-293 cells having the Flp Recombination Target
(FRT) site at the telomeric region of only one of the pair
of chromosomes 12 were transfected with the pcDNA5/
FRT/ABCB1 (2677G/T/A) and the Flp recombinase ex-
pression plasmid pOG44 vectors as previously reported
[19]. Single colonies resistant to hygromycin B (Life
Technologies) were picked and sub-cultured as Flp-In-
293/ABCB1 (2677G), Flp-In-293/ABCB1 (2677 T) and
Flp-In-293/ABCB1 (2677A) cells. Protein expression
levels of ABCB1 in these cells (2 × 107 cells) were
determined using Membrane Protein Extraction Kit
(BioVision, Milpitas, CA) and Human permeability
glycoprotein (P-gp/ABCB1) ELISA kit (Cusabio Biotech,
Wuhan, China) by a microplate reader (ARVOmx,
PerkinElmer, Waltham, MA).
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Cytotoxicity studies
In atorvastatin (Sigma-Aldrich, St Louis, Mo) cytotoxicity
experiment, HepaRG (5 × 105 cells/well), Flp-In-293/
ABCB1 (2677G), Flp-In-293/ABCB1 (2677 T) and Flp-In-
293/ABCB1 (2677A) cells were cultured in monolayers at
37 °C for 24 h in 24-well collagen type I-coated plates
(Iwaki Glass, Chiba, Japan). After the preculture, cells
were cultured in the presence of different concentrations
of atorvastatin 0, 0.3, 1, 3, 10, 30, 100 and 300 μM for
HepaRG cells, 0, 0.6, 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 mM for
Flp-In-293/ABCB1 (2677G/T/A) cells for 24 h. After the
culture, 50 μl of WST-8 working solution (Cell Counting
Kit-8, Dojindo Laboratories, Kumamoto, Japan) was added
to each well and the plates were incubated at 37 °C for 1 h
under 5 % CO2 and 95 % air. Optical density at 450 nm
was measured by a microplate reader (ARVOmx, Perki-
nElmer, Waltham, MA). Lactate dehydrogenase (LDH),
aspartate aminotransferase (AST) and ALT releases from
HepaRG cells into the medium were determined accord-
ing to the manufacturers’ protocol of LDH, AST and ALT
activity assay kits (Biovision, Milpitas, CA).
Statistical analysis
Association studies were conducted by using Fisher’s
exact test under an allelic model. P values were cor-
rected according to Bonferroni correction. A significance
level was set at 0.0029 (0.05/17) in Table 1. In case of
ABCB1 rs2032582, the patients were divided into two
groups (T/A versus G, G/A versus T or G/T versus A) to
evaluate the association of the three alleles by using the
Fisher’s exact test (Table 1). The haplotype analysis was
performed using SNPAlyze software (version. 8.0.1,
Dynacom, Chiba, Japan). Statistical analysis of cytotox-
icity test of HepaRG and ABCB1 protein expression
levels in Flp-In-293 cells was performed by using one-
way analysis of variance with Dunnett’s and Tukey’s
post-hoc test using GraphPad Prism software (version 6,
San Diego, CA). Cell viability was analyzed based on
four independent experiments performed in duplicate to
accurately estimate IC50 and statistical analysis of IC50
among three groups (2677G wild-type, 2677 T and
2677A alleles) was performed by using one-way analysis
of variance with Dunnett’s post-hoc test using GraphPad
Prism software.
Results
No significant association of disease background was ob-
served between AILI and non-AILI patients (Additional
file 1: Table S1). The median age values were 61 years
(range 27–82) and 66 years (32–89) in AILI and non-
AILI groups, respectively. The 60.0 and 53.9 % were
male in AILI and non-AILI groups, respectively. All
Table 1 Association of 15 functional SNPs in eight candidate genes with atorvastatin-induced liver injury




AILIa Non-AILIa RAF P valueb HWE
11 12 22 11 12 22 AILI Non-AILI ALLELIC DOM REC AILI Non-AILI
ABCB1 rs1045642 C/T I1145I C3435T 12 15 3 151 196 67 0.65 0.60 0.50 0.70 0.60 0.59 0.80
rs2032582 T, A/G S,T893A G2677 T/A 2 16 12 138 191 85 0.67 0.44 0.00068 0.0017 0.020 0.27 0.21
G, A/T A,T893S 15 14 1 158 193 63 0.73 0.61 0.073 0.24 0.10 0.29 0.75
G, T/A A,S893T 26 4 0 283 114 17 0.93 0.82 0.031 0.039 0.62 0.70 0.21
rs1128503 T/C G412G C1236T 15 12 3 146 197 71 0.70 0.59 0.10 0.12 0.45 0.79 0.74
ABCG2 rs2231142 C/A Q141K C421A 12 15 3 195 180 39 0.35 0.31 0.57 0.57 0.76 0.59 0.78
CYP2C9 rs1799853 C/T R144C CYP2C9*2 30 0 0 412 0 0 1.00 1.00 1.00 1.00 1.00 1.00 1.00
rs1057910 A/C I359L CYP2C9*3 28 2 0 393 20 0 0.03 0.02 0.66 0.65 1.00 0.85 0.61
CYP2C19 rs4244285 G/A P227P CYP2C19*2 16 9 5 197 180 36 0.32 0.31 0.88 0.58 0.18 0.09 0.57
rs4986893 G/A W212X CYP2C19*3 27 3 0 321 86 6 0.95 0.88 0.14 0.16 1.00 0.77 0.93
CYP3A4 rs12721627 C/G T185S CYP3A4*16 29 1 0 405 8 0 0.02 0.01 0.47 0.47 1.00 0.93 0.84
rs28371759 T/C L292P CYP3A4*18 29 1 0 399 14 0 0.98 0.98 1.00 1.00 1.00 0.93 0.73
CYP3A5 rs776746 G/A – CYP3A5*3 18 11 1 223 165 26 0.78 0.74 0.54 0.57 1.00 0.66 0.54
SLCO1B1 rs2306283 G/A N130D SLCO1B1*1B 14 12 4 185 179 50 0.67 0.66 1.00 0.85 0.77 0.58 0.51
rs4149056 T/C V174A SLCO1B1*5 18 11 1 306 95 13 0.22 0.15 0.14 0.13 1.00 0.66 0.10
UGT1A1 rs4148323 G/A G71R UGT1A1*6 25 5 0 281 118 15 0.92 0.82 0.075 0.10 0.61 0.62 0.55
rs8175347 (TA)6/(TA)7 – UGT1A1*28 23 7 0 332 76 6 0.12 0.11 0.83 0.64 1.00 0.47 0.49
Abbreviation: AILI atorvastatin-induced liver injury, RAF risk allele frequency, ALLELIC Allelic model, Dom Dominant model, REC Recessive model, HWE
Hardy–Weinberg equilibrium
aAILI, N = 30; Non-AILI, N = 414
bThe lowest significant P value after Bonferroni correction among three models is shown in bold (P < 0.0011)
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SNPs met quality control criteria (call rate > 95 %,
Hardy–Weinberg equilibrium P value > 10-3 and minor
allele frequency > 1 %). ABCB1 rs2032582 was found to
be associated with an increased risk of AILI (P =
0.00068, odds ratio (OR) = 2.59 with 95 % confidence
interval (CI) of 1.49–4.50, G allele versus T and A al-
leles) by genotyping 444 Japanese subjects for 15 func-
tional SNPs in eight candidate genes that reportedly
affect the pharmacokinetics of atorvastatin (Table 1). No
other polymorphisms showed a significant association
with AILI. The frequency for ABCB1 rs2032582 G allele
in AILI patients was significantly higher than that in
non-AILI patients whereas the frequencies of ABCB1
rs2032582 T and A alleles were not significantly different
between AILI and non-AILI groups, indicating that the
G allele might be a risk factor for AILI (Table 1 and
Additional file 1: Table S2). Although we performed
haplotype analysis using three SNPs of ABCB1
(rs1128503, rs2032582 and rs1045642), no haplotype
constructed from the SNPs showed an extremely smaller
P value than a single marker association of the ABCB1
rs2032582 (Table 2). No association of HLA-A, -B
and -C genotypes with AILI was shown (Additional
file 1: Table S3, Additional file 1: Table S4 and Additional
file 1: Table S5).
The cytotoxicity study using HepaRG cells demon-
strated concentration-dependent effects of atorvastatin
on cell viability as well as on LDH, AST and ALT release
from the cells (Additional file 1: Figure S1). To estimate
the effects of ABCB1 rs2032582 on cytotoxicity induced
by atorvastatin, we conducted cytotoxicity study using
Flp-In-293 cells stably expressing ABCB1 proteins
encoded by 2677G wild-type [Flp-In-293/ABCB1 (2677G)
cells], 2677A [Flp-In-293/ABCB1 (2677A) cells] and
2677 T [Flp-In-293/ABCB1 (2677 T) cells] alleles. No
significant differences were observed in ABCB1 protein
expression levels in Flp-In-293/ABCB1 (2677G/T/A) cells
(Additional file 1: Figure S2). The IC50 value in Flp-In-
293/Mock cells was about two-fold lower than those in
Flp-In-293/ABCB1 (2677G/T/A) cells, indicating higher
accumulation of atorvastatin in the Flp-In-293/Mock cells
compared to that in Flp-In-293/ABCB1 (2677G/T/A)
cells. The IC50 value in Flp-In-293/ABCB1 (2677G) cells
was significantly lower than those in Flp-In-293/ABCB1
(2677 T) and Flp-In-293/ABCB1 (2677A) cells (Table 3,
Additional file 1: Figure S3).
Discussion
To identify the genetic markers associated with AILI, we
genotyped 15 functional SNPs in eight genes that are
possibly involved in the hepatic metabolism (CYP2C9,
CYP2C19, CYP3A4, CYP3A5 and UGT1A1) and mem-
brane transport (ABCB1, ABCG2 and SLCO1B1) of ator-
vastatin. ABCB1 rs2032582 was significantly associated
with AILI. ABCB1 rs2032582 changes ABCB1 amino
acid 893 from alanine to serine or threonine, respect-
ively. These variants did not appear to affect ABCB1
protein expression levels in Flp-In-293/ABCB1 (2677G/
T/A) cells, but gave a lower IC50 in Flp-In-293/ABCB1
(2677G) cells than those in Flp-In-293/ABCB1 (2677 T/
A) cells. ATP-dependent uptake of [3H]-vincristine into
membrane vesicles is also reportedly slower in cells
expressing the ABCB1 rs2032582 G allele than those
expressing the ABCB1 rs2032582 T/A alleles [22].
Therefore, we speculate that patients carrying the
ABCB1 rs2032582 G allele experience lower atorvastatin
efflux activity from the hepatocytes into bile and higher
hepatocellular concentrations of atorvastatin than car-
riers of the ABCB1 rs2032582 T/A alleles. The higher
hepatocellular concentration of atorvastatin can increase
the risk of hepatotoxicity because atorvastatin induced
concentration-dependent cytotoxicity in HepaRG cells
(Additional file 1: Figure S1).
The ABCB1 rs2032582 allele frequencies in our 444
patients (45.2 %, 37.7 % and 17.1 % for G, T and A al-
leles, respectively) are consistent with the previous
Table 2 Association of haplotypes consisting of three SNPs of
ABCB1 with atorvastatin-induced liver injury
rs1128503 rs2032582 rs1045642 Number of carriers P valueb
AILIa (%) Non-AILIa (%)
T T T 15 (50.0) 237 (57.2) 0.45
C G C 11 (36.7) 158 (38.2) 1.00
T G C 16 (53.3) 126 (30.4) 0.014
C A C 4 (13.3) 128 (30.9) 0.060
T G T 3 (10.0) 25 (6.0) 0.45
T T C 0 (0.0) 24 (5.8) 0.39
C G T 2 (6.7) 11 (2.7) 0.22
T A C 0 (0.0) 5 (1.2) 1.00
C T T 0 (0.0) 2 (0.5) 1.00
C T C 0 (0.0) 2 (0.5) 1.00
Abbreviation: AILI atorvastatin-induced liver injury
aAILI, N = 30; Non-AILI, N = 414
bThe significant P value after Bonferroni correction is less than 0.005
Table 3 Atorvastatin-dependent cytotoxicity in Flp-In-293 cells
stably expressing different ABCB1 proteins
Cell name ABCB1 IC50 (mM) P value
Allele Amino acid Mean ± SE
Mock – – 2.74 ± 0.04 –
2677G wild-type G Alanine 5.44 ± 0.10 –
2677 T T Serine 6.02 ± 0.07 0.009
2677A A Threonine 5.95 ± 0.08 0.026
Abbreviation: SE standard error, CI confidence interval
Experiments were performed in duplicate wells and repeated four times. The
significant P value is shown in bold (P < 0.05, versus 2677G wild-type, one-way
analysis of variance with Dunnett’s post-hoc test)
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report of 154 Japanese subjects (42.9 %, 40.6 % and
16.6 % for G, T and A alleles, respectively) [23]. The
above report revealed that the ABCB1 rs2032582 G and
T/A allele frequencies in a Japanese population were
comparable with those in a Caucasian population
(42.9 % vs. 50.0 % and 57.2 % vs. 50.0 % for G and T/A
alleles, respectively) [23]. Taking into account that no
differences were reported in the systemic exposure to
atorvastatin between Asian and Caucasian subjects [24],
the ABCB1 rs2032582 allele might be also associated
with the risk of AILI in the Caucasian population.
Of the atorvastatin-induced adverse reactions, myop-
athy is one of the most fatal adverse reactions [25, 26].
No statistically significant difference in AUC and the
maximum plasma concentrations was observed between
14 patients with atorvastatin-induced myopathy and 15
healthy controls [27]. However, patients with
atorvastatin-induced myopathy showed 2.4- and 3.1-fold
higher AUC to atorvastatin lactone and p-hydroxy ator-
vastatin, respectively, compared to controls [27]. Atorva-
statin is converted to its corresponding lactone form
spontaneously or via glucuronidation mediated by
UGT1A1, 1A3 and 1A4 and is metabolized to p-hydroxy
atorvastatin by CYP3A4/5 [11, 28]. The present associ-
ation studies showed that known functional SNPs of
UGT1A1 and CYP3A4/5 were not associated with AILI.
The higher accumulation of atorvastatin in the liver of
patients carrying the ABCB1 rs2032582 G allele may
cause hepatotoxicity, rather than those of atorvastatin
lactone and p-hydroxy atorvastatin, the atorvastatin me-
tabolites generated by UGT1A1 and CYP3A4/5. There-
fore, the genetic markers might differ between liver
injury and myopathy induced by atorvastatin.
In general, DILI can be divided into dose-dependent
and idiosyncratic types [29]. The former is related to the
pharmacokinetics and/or pharmacological actions of the
drug and the latter is related to immune systems, such
as human leukocyte antigen (HLA) in a dose-
independent manner. In fact, several HLA alleles showed
drug-specific associations with DILI, such as HLA-
A*33:03 for ticlopidine and HLA-B*57:01 for flucloxa-
cillin [30]. Therefore, we examined association of HLA
alleles with AILI. However, no significant association
was observed for HLA-A, -B and -C alleles with AILI
(Additional file 1: Table S3, Additional file 1: Table S4
and Additional file 1: Table S5).
Conclusions
Our results showed that ABCB1 rs2032582 was associ-
ated with an increased risk of AILI in the Japanese
population. A genetic test of ABCB1 rs2032582 may pro-
vide useful information for predicting individuals at
higher risk of AILI. However, additional studies with
larger sample size are needed before applying this gen-
etic marker in clinical practice.
Additional file
Additional file 1: Fig. S1 Atorvastatin concentration-dependent
cytotoxicity on HepaRG cells. Fig. S2 Expression levels of ABCB1 protein in
Flp-In-293 cells stably expressing ABCB1 proteins encoded by 2677G
wild-type, 2677 T and 2677A alleles. Fig. S3 Cell viability curve for IC50
determination in Flp-In-293 cells stably expressing ABCB1 proteins
encoded by 2677G wild-type, 2677 T and 2677A alleles. Table S1 Distribution
of disease status in 30 AILI and 414 non-AILI patients registered in BioBank
Japan. Table S2 Frequency of rs2032582 in 30 AILI and 414 non-AILI patients.
Table S3 Association of HLA-A alleles with atorvastatin-induced liver injury.
Table S4 Association of HLA-B alleles with atorvastatin-induced liver injury.
Table S5 Association of HLA-C alleles with atorvastatin-induced liver injury.
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